Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Advanced Gold Exploration Announces Private Placement (click to learn more) Nexera Energy Increases Ownership in Marpat Leases (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sellas Life Sciences Group Inc SLS

Healthcare Biotechnology
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in 20 or more cancer types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers, and solid tumor indications. The Company is also developing GFH009, a small molecule, selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.


NDAQ:SLS - Post by User

Sellas Life Sciences Group Inc
Bullboard Posts
User Avatar Image
(0)
•••
  • BluSignalsX
Post by BluSignalson Apr 02, 2018 3:46pm
115 Views
Post# 27816560

Great Upward Trend!

Great Upward Trend!
SLS has seen a lot of turbulence, with mid - March having a downward trend.  However, the sudden turn today was a great advantage for many.  The turn was based on the product data which shows great promise as well as a buy and hold by the company. 

SLS leading indicators were able to show patterns of how this was moving in the market before it happened.  A lot of profitability to those who were looking at the opportunity and received alerts.


See more: https://www.blusignalsystems.com/sls-stock-going-up-leading-indicators-saw-first/
Bullboard Posts